SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0
Launched by HELIOS KLINIKEN SCHWERIN · Nov 8, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0, is exploring a new way to teach a medical procedure known as Endoscopic Retrograde Cholangiopancreaticography (ERCP), which is used to treat problems in the bile and pancreatic ducts. The study aims to find out if using SmartGlasses for remote guidance is just as effective and safe as having an instructor physically present during the procedure. A key part of the study is measuring how quickly the doctor can successfully access the bile or pancreatic ducts, which is important for the success of the treatment.
To participate, adults aged 18 and older who have not had a certain type of previous surgery on the papilla may be eligible. However, those who require a different type of procedure, have serious health issues, are pregnant, or cannot provide consent will not be included. Participants can expect to be part of a research study that aims to improve how doctors are trained to perform this important procedure, potentially making it safer and more efficient in the future. The trial is not yet recruiting participants, so there will be announcements when it starts.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Adult patients aged ≥ 18 years without previous papillotomy Exclusion criteria
- • Cannulation of the minor papilla necessary
- • Significant comorbidity
- • Haemodynamic instability
- • Pregnant women
- • Refusal or inability to give written informed consent for the study
- • Instructor had to perform the examination himself/herself
About Helios Kliniken Schwerin
Helios Kliniken Schwerin is a leading healthcare institution in Germany, specializing in a comprehensive range of medical services and innovative clinical research. As part of the Helios Health Group, one of the largest private hospital operators in Europe, Helios Kliniken Schwerin is dedicated to advancing medical science through rigorous clinical trials. The institution is committed to enhancing patient care and outcomes by exploring new treatments and therapies in a collaborative environment that prioritizes safety and ethical standards. With a focus on multidisciplinary approaches and state-of-the-art facilities, Helios Kliniken Schwerin plays a pivotal role in contributing to the advancement of medical knowledge and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Schwerin, , Germany
Schwerin, Mecklenburg Vorpommern, Germany
Patients applied
Trial Officials
Daniel Schmitz, Dr.med.
Principal Investigator
Helios Kliniken Schwerin
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported